Saudi experts statement on advancing multiple myeloma treatment: the evolving role of bispecific antibodies
BsAbs are an effective treatment option for those with triple-class refractory MM and this manuscript provides a framework to support their optimal use in Saudi Arabia.
Authors
- Ayman Y. Alhejazi
- Saud Alhayli
- Abdullah Saleh (ORCID: https://orcid.org/0000-0002-0934-3160)
- Omar Abduljalil
- Enas Mutahar
- Ahmed Salleh Barefah
- Majed Alahmadi
- Ahmad Alsaeed
- Abdullah Alamer
- Ghazi S. Alotaibi
- Hesham Kiwan
Institutions
- Pfizer (United States) (US)
- King Abdulaziz University (SA)
- King Saud bin Abdulaziz University for Health Sciences (SA)
- King Faisal Specialist Hospital & Research Centre (SA)
- King Saud University (SA)
- King Fahad Specialist Hospital (SA)
- King Abdulaziz Medical City (SA)
- King Abdullah International Medical Research Center (SA)
- King Fahad Hospital Jeddah (SA)
- National Guard Health Affairs (SA)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-01-21
- DOI
- https://doi.org/10.3389/fmed.2025.1730261
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00